Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients.

ABSTRACT:

Background

Bamlanivimab and casirivimab-imdevimab are authorized for emergency use treatment of mild to moderate coronavirus disease 2019 (COVID-19) in patients at high risk for developing severe disease or hospitalization. Their safety and efficacy have not been specifically evaluated in solid organ transplant recipients.

Methods

We retrospectively reviewed solid organ transplant recipients who received monoclonal antibody infusion for COVID-19 at Mayo Clinic sites through January 23, 2021. Outcomes included emergency department visit, hospitalization, mortality, and allograft rejection.

Results

Seventy-three patients were treated, most commonly with bamlanivimab (75.3%). The median age was 59 years, 63% were male, and the median Charlson comorbidity index was 5. Tra

SUBMITTER: Yetmar ZA 

PROVIDER: S-EPMC8494079 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature